Corcept Therapeutics CORT Accretion of marketable securities, net

Other financials

Revenue$164.9M+4.9%

Gross profit$162.0M+4.7%

Operating income-$49.6M-1,552%

Net income-$31.8M-255%

EPS (diluted)-$0.30-276%

Cash & equivalents$110.0M+21.1%

Total debt$9.6M+41.0%

Total equity$638.0M-6.6%

Total assets$814.9M-3.7%

Operating cash flow-$16.8M-452%

CapEx$201.0K+93.3%

Free cash flow-$17.0M-464%

Market cap$8.58B-64.4%

Enterprise value$8.48B-65.0%

P/E181.2×+1.3×

P/S11.2×-24.0×

Gross margin98.3%-0.2pp

Operating margin-1.1%-17.2pp

Net margin6.2%-13.4pp

FCF margin15.6%-10.2pp

Return on equity7.2%-14.6pp

Debt / equity0×0.0×

Current ratio2.9×-0.2×

Reported directly by Corcept Therapeutics in its filing.

Tagged under the XBRL concept cort:AccretionExpenseIncome.

The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Corcept Therapeutics's accretion of marketable securities, net?: Corcept Therapeutics (CORT) reported accretion of marketable securities, net of -$836K in Q1 2026.
How has Corcept Therapeutics's accretion of marketable securities, net changed year-over-year?: Corcept Therapeutics's accretion of marketable securities, net increased by 50.6% year-over-year, from -$1.69M to -$836K.